A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort
about
Biomarkers for prostate cancer: present challenges and future opportunities.Clinical Utility of Biomarkers in Localized Prostate Cancer.Improving the evaluation and diagnosis of clinically significant prostate cancer in 2017.A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy.Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above.The 4Kscore blood test accurately identifies men with aggressive prostate cancer prior to prostate biopsy with or without DRE information.Predicting Low-Risk Prostate Cancer from Transperineal Saturation Biopsies.Clinical performance of the 4Kscore Test to predict high-grade prostate cancer at biopsy: A meta-analysis of us and European clinical validation study results.A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies.A Novel Diagnostic Tool for Selecting Patients With Mesenchymal-Type Colon Cancer Reveals Intratumor Subtype Heterogeneity.Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.Emerging biomarkers in the diagnosis of prostate cancer.Development and internal validation of PI-RADs v2-based model for clinically significant prostate cancer.
P2860
Q37474443-9747ECDE-F185-40EC-B8A3-D6E121251594Q38792354-C1213853-E813-4793-BA9A-6A004EE1AFEDQ38950445-1CC91126-B03F-492D-B1D7-3CC31A7F724FQ38957244-20B63339-2C3F-4E89-B7D3-E43BF4CD8317Q39331903-C8F19DE7-C10E-4B60-9AA0-CE19B8459DF9Q40469023-01E578EA-C1DB-42FD-A4D6-68723DBE6E36Q40541815-796B7CA2-5B5E-45CC-8D8A-78F3A5DF9777Q47568399-39781685-C351-4F9E-8AE6-80B8F3203712Q47759609-8759DF42-57E4-467D-ADF5-D6DD9EA73977Q48520586-B5C91DB7-7383-4B83-B4C3-9FCF5D395FB0Q49710514-3CAFBB13-343B-4CC1-A94F-80EE275EE852Q51071981-2DDC5C99-379C-4D1D-8DD2-6D6AA5137D5DQ52665993-14AF7858-7B76-4AA5-B969-49013699A0E3Q54964875-B51CEC20-E56B-46F3-87B2-E6D804B56A8AQ55007094-B252DE13-8676-46B2-A223-3B5D64570CA4
P2860
A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
A Four-kallikrein Panel Predic ...... lidation in a Community Cohort
@ast
A Four-kallikrein Panel Predic ...... lidation in a Community Cohort
@en
type
label
A Four-kallikrein Panel Predic ...... lidation in a Community Cohort
@ast
A Four-kallikrein Panel Predic ...... lidation in a Community Cohort
@en
prefLabel
A Four-kallikrein Panel Predic ...... lidation in a Community Cohort
@ast
A Four-kallikrein Panel Predic ...... lidation in a Community Cohort
@en
P2093
P2860
P1433
P1476
A Four-kallikrein Panel Predic ...... lidation in a Community Cohort
@en
P2093
Anders S Bjartell
Andrew J Vickers
Daniel D Sjoberg
Hans Lilja
Katharina Braun
P2860
P304
P356
10.1016/J.EURURO.2015.04.028
P407
P577
2015-05-12T00:00:00Z